Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBITDA (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed EBITDA for 8 consecutive years, with -$92.5 million as the latest value for Q1 2026.

  • Quarterly EBITDA fell 47.14% to -$92.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$315.3 million through Feb 2026, down 36.69% year-over-year, with the annual reading at -$285.7 million for FY2025, 34.1% down from the prior year.
  • EBITDA for Q1 2026 was -$92.5 million at Nurix Therapeutics, down from -$83.1 million in the prior quarter.
  • The five-year high for EBITDA was -$26.8 million in Q2 2023, with the low at -$92.5 million in Q1 2026.
  • Average EBITDA over 5 years is -$54.7 million, with a median of -$48.3 million recorded in 2025.
  • The sharpest move saw EBITDA skyrocketed 41.45% in 2023, then crashed 81.36% in 2024.
  • Over 5 years, EBITDA stood at -$48.7 million in 2022, then grew by 6.89% to -$45.3 million in 2023, then plummeted by 42.62% to -$64.7 million in 2024, then fell by 28.52% to -$83.1 million in 2025, then dropped by 11.31% to -$92.5 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$92.5 million, -$83.1 million, and -$91.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.